Patent 6733994 Issued on May 11, 2004. Estimated Expiration Date: October 4, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide536/23.1DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)
The present invention provides methods of producing protein in a recombinant expression system that comprises translation of mRNA transcribed from a heterologous DNA sequence in the expression system, said method comprising the steps of predicting the secondary structure of mRNA transcribed from a native heterologous DNA sequence; modifying the native heterologous DNA sequence to produce a modified heterologous DNA sequence wherein mRNA transcribed from the modified heterologous DNA sequence has a secondary structure having increased free energy compared to that of the secondary structure of the mRNA transcribed from the native heterologous DNA sequence; and using the modified heterologous DNA sequence in the recombinant expression system for protein production. The invention also provides injectable pharmaceutical compositions comprising a nucleic acid molecule that includes a modified coding sequence. The invention also provides recombinant viral vectors comprising a nucleic acid molecule that includes a modified coding sequence.
Other References
Chaudhary, V. et al., “A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins,” Proc Natl Acad Sci USA, 1990, 87, 1066.
Freier, S. et al., “Improved free-energy parameters for predictions of RNA duplex stability,” Proc Natl Acad Sci USA, 1986, 83, 9373-9377.
Jaeger, J. et al., “Improved predictions of secondary structures for RNA,” Proc Natl Acad Sci USA, 1989, 86, 7706-7710.
Howell, M. et al., “Limited T-cell receptor β-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis,” Proc Natl Acad Sci USA, 1991, 88, 10921-10925.
Kim, C. et al., “Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells,” Gene 1991, 199, 293-301.
Oksenberg, J. et al., “Limited heterogeneity of rearranged T-cell receptor V α transcripts in brains of multiple sclerosis patients,” Nature, 1990 345, 344-346.
Paliard, X. et al., “Evidence for the Effects of a Superantigen in Rheumatoid Arthritis,” Science, 1991, 253, 325-329.
Williams, W. et al., “Restricted Heterogeneity of T Cell Receptor Transcripts in Rheumatoid Synovium,” J Clin Invest, 1992, 90, 326-333.
Wucherpfennig, K. et al., “Shared Human T Cell Receptor VβUsage to Immunodominant Regions of Myelin Basic Protein,” Science, 1990, 248, 1016-1019.
Zuker, M., “On finding all suboptimal foldings of an RNA molecule,” Science, 1989, 244, 48-52.
de Smit, M.H., et al “Control of translation by mRNA secondary structure in Escherichia coli,” J. Mol. Biol., 1994, 244, 144-150.
Mukund, M.A., et al., “Effect of mRNA secondary structure in the regulation of gene expression: unfolding of stable loop causes the expression of Taq polymerase in E. coli,” Current Science, Jun. 10, 1999, 76(11), 1486-1490.
Suo, Z., et al., “RNA secondary structure switching during DNA synthesis catalyzed by HIV-1 reverse transcriptase,” Biochemistry, 1997, 36, 14778-14785.
October 4, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
